Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.35 |
| ▸ | PER2 | O15055 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109589 | 0.89 | CNR2 (0.41) | CYP2D6SMN1; SMN2HPGDTSHRCYP2C9 | |
| SCHEMBL16525749 | 0.84 | HPGD (0.37) | CYP2D6SMN1; SMN2HPGDTSHRCYP2C9 | |
| SCHEMBL24401223 | 0.84 | PER2 (0.38) | KDM1APER2POLB | |
| Bromide SCHEMBL28911957 | 0.82 | HPGD (0.36) | CYP2D6SMN1; SMN2HPGDTSHRCYP2C9 | |
| SCHEMBL14726015 | 0.81 | CYP2D6 (0.59) | CYP2D6CYP2C9GPBAR1POLB | |
| SCHEMBL1102007 | 0.80 | ALDH1A1 (0.48) | TSHRMAOAMAOBPOLB | |
| SCHEMBL16940692 | 0.77 | KMT2A (0.44) | CYP2D6CYP2C9GPBAR1POLB | |
| SCHEMBL26092407 | 0.77 | ALDH1A1 (0.35) | KDM1APER2 | |
| SCHEMBL18352973 | 0.77 | HPGD (0.42) | CYP2D6SMN1; SMN2HPGDTSHRCYP2C9 | |
| SCHEMBL7561562 | 0.77 | NOTUM (0.53) | SMN1; SMN2HPGDKDM1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397656-A2 | HDAC6 INHIBITORS AND IMAGING AGENTS | The General Hospital Corporation (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20220133916-A1 | HDAC6 Inhibitors and Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-11207431-B2 | HDAC6 inhibitors and imaging agents | THE GENERAL HOSPITAL CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200054773-A1 | HDAC6 Inhibitors and Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2020-02-20 | — | — | US | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | CYP2D6 451/4885SMN1; SMN2 3670/4885HPGD 195/4885 |
| US-20200054773-A1 | HDAC6 Inhibitors and Imaging Agents | HDAC1, HDAC6, HDAC11 | CYP2D6 4740/4885SMN1; SMN2 1829/4885HPGD 1362/4885 |
| US-11207431-B2 | HDAC6 inhibitors and imaging agents | HDAC1, HDAC6, HDAC11 | CYP2D6 4740/4885SMN1; SMN2 1829/4885HPGD 1362/4885 |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | KRAS, NRAS, HRAS | CYP2D6 4317/4885SMN1; SMN2 2930/4885HPGD 2410/4885 |
| US-20220133916-A1 | HDAC6 Inhibitors and Imaging Agents | HDAC1, HDAC6, HDAC11 | CYP2D6 4740/4885SMN1; SMN2 1829/4885HPGD 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.